A 1.125mg microdose option for patients who cannot tolerate the standard 2.5mg starting dose
This change is a critical factor in deciding the ideal transition period to retatrutide, as it ensures a smooth shift without overlapping or diminished effects
Increased public understanding of obesity as a cardiometabolic conditionrather than a purely lifestyle issue, strengthens interest in treatments that offer clinically proven improvements in heart health, glycemic control and long-term weight management
Sleep Optimization Deepens Sleep quality that improved during weeks one and two continues advancing
In contrast, GLP-1 medication side effects are more likely to include nausea, reduced appetite, or mild gastrointestinal discomfort
Researchers wanted to determine whether the effects extended across multiple forms of addiction and whether the drugs could help reduce the most serious consequences associated with substance use disorders